- Home
- Companies
- north america
- non muscle invasive bladder cancer
Refine by
Non Muscle Invasive Bladder Cancer Suppliers In North America
6 companies found
based inToronto, ONTARIO (CANADA)
Theralase was one of the first companies in North America to bring CLT to patients and the first company in the world to bring personalized ACT to patients individual tissue characteristics. With our multi-discipline experience in physics, ...
Theralase is laser focused on advancing the cutting-edge Anti-Cancer Therapy (“ACT”) towards commercialization, providing an alternative treatment methodology for Non-Muscle ...
based inPrinceton, NEW JERSEY (USA)
Cysview is a pharmaceutical product that makes non-muscle invasive bladder cancer tumors glow bright pink under blue light during a cystoscopy. Because the cancer is more visible, urologists can remove it more completely than if they weren’t using ...
A cystoscopy is a medical procedure where a urology healthcare professional uses a thin, tube-like telescope called a cystoscope to look directly into the bladder for a close examination of the lining. This procedure is used to help find the cause ...
based inNew York, NEW YORK (USA)
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies ...
TARA-002 is an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). ...
based inAuburndale, MASSACHUSETTS (USA)
Imagin Medical, a surgical imaging company, is focusing on bladder cancer, the sixth most prevalent cancer in the U.S. and the third most common cancer in men. It is the most expensive form of cancer to treat over the lifetime of a patient because ...
Introduced in 2010, blue light cystoscopy, uses blue-filtered white light to address the limitations of white light cystoscopy. This method involves administering a contrast agent into the bladder which is absorbed by the cancerous cells, causing ...
based inPrinceton, NEW YORK (USA)
We are a biopharmaceutical company dedicated to building novel solutions that treat urothelial and specialty cancers. Our breakthrough therapy and innovative clinical pipeline aim to maximize the potential benefit of local delivery with our novel ...
UroGen is developing UGN-102 (mitomycin) for intravesical solution as a primary nonsurgical alternative to repetitive TURBT. UGN-102 is an investigational formulation that utilizes our innovative technology, RTGel™ reverse-thermal hydrogel, ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Avelumab (anti-PD-L1) is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated ...